Trial · NCT01066819
Adverse events144
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 144
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Depression | Psychiatric disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 234 | 1,441 | |
| other | Insomnia | Psychiatric disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 224 | 1,441 | |
| other | Anxiety | Psychiatric disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 92 | 1,441 | |
| other | Anaemia | Blood and lymphatic system disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 333 | 1,441 | |
| other | Neutropenia | Blood and lymphatic system disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 108 | 1,441 | |
| other | Fatigue | General disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 206 | 1,441 | |
| other | Influenza like illness | General disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 104 | 1,441 | |
| other | Irritability | General disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 74 | 1,441 | |
| other | Rash | Skin and subcutaneous tissue disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 138 | 1,441 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 80 | 1,441 | |
| other | Nausea | Gastrointestinal disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 168 | 1,441 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 78 | 1,441 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 75 | 1,441 | |
| other | Headache | Nervous system disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 136 | 1,441 | |
| other | Decreased appetite | Metabolism and nutrition disorders | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 79 | 1,441 | |
| serious | Pneumonia | Infections and infestations | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 10 | 1,441 | |
| serious | Cellulitis | Infections and infestations | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 3 | 1,441 | |
| serious | Appendicitis | Infections and infestations | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 1 | 1,441 | |
| serious | Appendicitis perforated | Infections and infestations | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 1 | 1,441 | |
| serious | Bronchitis | Infections and infestations | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | 1 | 1,441 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01066819/events